Semaglutide in Adults with Type 1 Diabetes and Obesity.

Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK

NEJM evidence23 Jun 2025Cited by 42 (Europe PMC)

PMID40550013DOI10.1056/evidoa2500173PepBankPUB-40550013

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity using automated insulin delivery, 36% on semaglutide vs 0% on placebo reached the primary composite outcome at 26 weeks.
In plain wordsIn adults with type 1 diabetes and obesity, more people on semaglutide than placebo reached the combined glucose and weight goal.
Peptide
Semaglutide
Outcome
IncreasePrimary composite (time in range above 70%, time below range under 4%, and weight loss of at least 5%)
Study
n = 72
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg once weekly · 26 weeksAs given in this study (human).
Measurements
Patients achieving primary composite
36%
semaglutide
Patients achieving primary composite
0%
placebo
Source sentences
Summary
A significantly greater percentage of patients in the semaglutide group than in the placebo group achieved the primary composite outcome (36% vs. 0%; between-group difference, 36 percentage points; 95% confidence interval [CI], 20.6 to 52.2; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind trial, we randomly assigned 72 adults with type 1 diabetes using an automated insulin delivery (AID) system and with a body mass index of 30 or higher in a 1:1 ratio to receive once-weekly semaglutide up to 1 mg or placebo.
Report a problemFND-4055001301
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity using automated insulin delivery, semaglutide lowered HbA1c more than placebo (difference -0.3 percentage points).
In plain wordsIn adults with type 1 diabetes and obesity, semaglutide lowered HbA1c slightly more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change from baseline to week 26
Study
n = 72
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg once weekly · 26 weeksAs given in this study (human).
Measurements
Difference in HbA1c change
−0.3 percentage points
semaglutide versus placebo
Source sentences
Summary
The difference in the least-squares mean change from baseline to week 26 for the semaglutide versus placebo group for glycated hemoglobin was -0.3 percentage points (95% CI, -0.6 to -0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind trial, we randomly assigned 72 adults with type 1 diabetes using an automated insulin delivery (AID) system and with a body mass index of 30 or higher in a 1:1 ratio to receive once-weekly semaglutide up to 1 mg or placebo.
Report a problemFND-4055001302
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity using automated insulin delivery, semaglutide increased time in glucose range 70 to 180 mg/dl more than placebo (difference 8.8 percentage points).
In plain wordsIn adults with type 1 diabetes and obesity, semaglutide gave more time with glucose in the target range than placebo.
Peptide
Semaglutide
Outcome
IncreaseTime with CGM glucose 70 to 180 mg/dl
Study
n = 72
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg once weekly · 26 weeksAs given in this study (human).
Measurements
Difference in time in range 70-180 mg/dl
8.8 percentage points
semaglutide versus placebo
Source sentences
Summary
for percentage of time with CGM glucose levels between 70 and 180 mg/dl it was 8.8 percentage points (95% CI, 3.9 to 13.7)
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind trial, we randomly assigned 72 adults with type 1 diabetes using an automated insulin delivery (AID) system and with a body mass index of 30 or higher in a 1:1 ratio to receive once-weekly semaglutide up to 1 mg or placebo.
Report a problemFND-4055001303
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity using automated insulin delivery, semaglutide reduced body weight more than placebo (difference -8.8 kg).
In plain wordsIn adults with type 1 diabetes and obesity, semaglutide led to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseBody weight change from baseline to week 26
Study
n = 72
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 1 mg once weekly · 26 weeksAs given in this study (human).
Measurements
Difference in body weight change
−8.8 kg
semaglutide versus placebo
Source sentences
Summary
and for body weight it was -8.8 kg (95% CI, -10.6 to -7.0).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind trial, we randomly assigned 72 adults with type 1 diabetes using an automated insulin delivery (AID) system and with a body mass index of 30 or higher in a 1:1 ratio to receive once-weekly semaglutide up to 1 mg or placebo.
Report a problemFND-4055001304
05HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes and obesity, two severe hypoglycemia events occurred in each group, semaglutide and placebo.
In plain wordsIn adults with type 1 diabetes and obesity, severe low blood sugar happened twice in each group.
Peptide
Semaglutide
Outcome
No significant changeSevere hypoglycemia events
Study
n = 72
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
There were two severe hypoglycemia events in each group
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind trial, we randomly assigned 72 adults with type 1 diabetes using an automated insulin delivery (AID) system and with a body mass index of 30 or higher in a 1:1 ratio to receive once-weekly semaglutide up to 1 mg or placebo.
Report a problemFND-4055001305
06HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes and obesity, no diabetic ketoacidosis was reported.
In plain wordsIn adults with type 1 diabetes and obesity, no cases of diabetic ketoacidosis were reported.
Peptide
Semaglutide
Outcome
No significant changeDiabetic ketoacidosis
Study
n = 72
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
and no diabetic ketoacidosis was reported.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind trial, we randomly assigned 72 adults with type 1 diabetes using an automated insulin delivery (AID) system and with a body mass index of 30 or higher in a 1:1 ratio to receive once-weekly semaglutide up to 1 mg or placebo.
Report a problemFND-4055001306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT05537233

ADJUnct Semaglutide Treatment in Type 1 Diabetes

Viral N. Shahn = 11511 Apr 2023 to 6 Aug 2024

Type 1 Diabetes · Obesity

Trial page ClinicalTrials.govUpdated 3 Sept 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.